Stockscreener 앱 받기
124.81
0.22%
0.27
시장 영업 전:
124.20
-0.61
-0.49%
전일 마감가:
$124.54
열려 있는:
$124.01
하루 거래량:
1.63M
Relative Volume:
0.26
시가총액:
$217.03B
수익:
$43.84B
순이익/손실:
$13.90B
주가수익비율:
15.66
EPS:
7.9725
순현금흐름:
$6.92B
1주 성능:
-1.50%
1개월 성능:
-1.87%
6개월 성능:
-9.61%
1년 성능:
+8.76%
1일 변동 폭
$124.00
$125.33
1주일 범위
$123.76
$127.58
52주 변동 폭
$110.86
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
124.81 | 216.56B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.13 | 142.45B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.74 | 135.69B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.27 | 124.96B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
86.29 | 50.04B | 5.88B | 1.34B | 799.60M | 2.3489 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
V. M. Manning & CO. Inc. Makes New $2.70 Million Investment in Abbott Laboratories $ABT - MarketBeat
What You Need to Know Ahead of Abbott Laboratories' Earnings Release - Barchart.com
Abbott Laboratories Pakistan : Corporate Briefing Session 2025 - marketscreener.com
Avanza Fonder AB Purchases 10,889 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT) News and Stock Outlook on Dec. 25, 2025: FDA Clears Volt PFA, FreeStyle Libre Alert Persists, Exact Sciences Deal Looms - ts2.tech
Abbott Laboratories Stock (ABT) After Hours on Dec. 24, 2025: What to Know Before the Next Market Open on Dec. 26 - ts2.tech
Abbott Laboratories Shrugs Off Tariffs & China Headwinds With 7% Dividend Raise (NYSE:ABT) - Seeking Alpha
Swedbank AB Sells 179,009 Shares of Abbott Laboratories $ABT - MarketBeat
Vontobel Holding Ltd. Sells 1,389,990 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Purchased by IFM Investors Pty Ltd - MarketBeat
GLOBALT Investments LLC GA Boosts Stock Position in Abbott Laboratories $ABT - MarketBeat
DAVENPORT & Co LLC Has $127.05 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock After Hours (ABT): FDA Win, Holiday Trading Dynamics, and What to Watch Before the Dec. 24 Open - ts2.tech
Abbott Laboratories (ABT) director Nita Ahuja files Form 3 with no securities owned - Stock Titan
Abbott India Limited (NSE:ABBOTINDIA) stock most popular amongst public companies who own 75%, while individual investors hold 17% - simplywall.st
Abbott Stock May Benefit Following Volt PFA's FDA Approval - Nasdaq
Is Abbott Laboratories Attractively Priced After Recent Share Price Gains And DCF Concerns? - Yahoo Finance
Abbott Wins FDA Clearance for Volt - Yahoo Finance
Abbott Laboratories $ABT Shares Sold by Exchange Traded Concepts LLC - MarketBeat
Abbott Laboratories: Buy Rating Backed by Volt PFA-Driven Incremental Growth and Strengthening Electrophysiology Position - TipRanks
A pleasant shock: Abbott’s Volt PFA system snags early FDA approval - BioWorld MedTech
Abbott Enters the US Pulsed Field Ablation Fray - Medical Device and Diagnostic industry
Abbott receives clearance for heart delivery device in premature babies - MedTech Dive
Abbott Claws Back More Glucose Monitoring IP On Appeal - Law360
Broadcom Just Raised Its Dividend—But It’s Not the Only One Signaling Strength - Investing.com
Abbott's Volt pulsed field ablation system scores FDA approval - Fierce Biotech
Abbott's FDA OK of Volt signals big 2026 for its cardiology business - Crain's Chicago Business
Abbott receives FDA approval for Volt PFA system - MedTech Dive
Abbott PFA system gains FDA approval - Cardiovascular Business
Abbott Secures US FDA Approval for Volt Pulsed Field Ablation System for Heart Rhythm Disorder - marketscreener.com
Abbott wins FDA approval of Volt pulsed ablation device for atrial fibrillation - Seeking Alpha
Abbott Gets FDA Approval for Volt Medical Device to Treat Arrhythmia - marketscreener.com
Abbott Labs stock gains as FDA approves Volt PFA System ahead of schedule - Investing.com
Abbott earns FDA approval for Volt PFA system for AFib - MassDevice
New heart procedure uses electric pulses to treat common irregular rhythm - Stock Titan
Abbott Laboratories $ABT Shares Sold by USA Financial Formulas - MarketBeat
Investors in Abbott Laboratories (NYSE:ABT) have seen returns of 27% over the past five years - Yahoo Finance
CCLA Investment Management Acquires 66,275 Shares of Abbott Laboratories $ABT - MarketBeat
21,438 Shares in Abbott Laboratories $ABT Purchased by Trust Point Inc. - MarketBeat
CHICAGO TRUST Co NA Sells 72,337 Shares of Abbott Laboratories $ABT - MarketBeat
Charles Schwab Trust Co Has $3.94 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Voya Investment Management LLC Lowers Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Meadowbrook Wealth Management LLC Acquires New Stake in Abbott Laboratories $ABT - MarketBeat
Abbott’s biowearable: One sensor for glucose, ketones - Abbott
Abbott Laboratories $ABT Shares Sold by Teamwork Financial Advisors LLC - MarketBeat
Abbott secures FDA and CE Mark approvals for Amplatzer delivery system - Medical Device Network
Abbott Laboratories $ABT Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Miniature Heart Device And Wider Lingo Access Could Be A Game Changer For Abbott (ABT) - simplywall.st
Abbott wins appeal to restore glucose monitoring patent - Life Sciences Intellectual Property Review
Abbott's Amplatzer Piccolo Delivery System Receives FDA Clearance, CE Mark - Diagnostic and Interventional Cardiology
Abbott (ABT): Assessing Valuation After New Regulatory Wins for Its Pediatric Heart Device Innovation - Yahoo Finance
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.04%
0.02%
자본화:
|
볼륨(24시간):